跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
GLASSIA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
GLASSIA
Authorized
STANDARD
GLASSIA
takeda canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ac5bffdcc9fa3677
Company
takeda canada inc
Type
Standard
Approval Details
Approval Id
ac5bffdcc9fa3677
Drug Approval Canada Name
GLASSIA
Product Name
GLASSIA
Status
Marketed
Status Date
2024-01-02
Original Market Date
2024-01-02
Din
02522438
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D
Ahfs
44:00.00
Atc Original
B02AB02 ALFA1 ANTITRYPSIN
Atc Name
b 02 ab 02
Aig Number
0120888004
Company Name
takeda canada inc
Company Address
3800, 22 Adelaide Street West, Toronto, Ontario, Canada, M5H 4E3
Active Ingredients
ALPHA1-PROTEINASE INHIBITOR (HUMAN)
1000 MG / 50 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ac5bffdcc9fa3677
Type
Standard
Back to Health Canada Approvals